(Q34572050)

3 August 2017

1 reference

title

Circadian chronotherapy for human cancers (English)

1 reference

3 August 2017

0 references

F Lévi

1

1 reference

3 August 2017

publication date

1 May 2001

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

307-315

1 reference

Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

A serum shock induces circadian gene expression in mammalian tissue culture cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Molecular bases for circadian clocks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Interacting molecular loops in the mammalian circadian clock

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Melatonin's role in vertebrate circadian rhythms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Circadian rhythms and cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Circadian variation in the expression of cell-cycle proteins in human oral epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Positional cloning of the mouse circadian clock gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Circadian-system alterations during cancer processes: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Circadian timing of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Clinical pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronothe

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Factors influencing the natural history of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Diurnal cortisol rhythm as a predictor of breast cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

The pattern of hormonal circadian time structure (acrophase) as an assessor of breast-cancer risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Incidence of cancer among commercial airline pilots

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900326-0

7 January 2021

10.1016/S1470-2045(00)00326-0

Identifiers

DOI

1 reference

3 August 2017

1 reference